2020
DOI: 10.3389/fneur.2020.584446
|View full text |Cite|
|
Sign up to set email alerts
|

Effectiveness of Mycophenolate Mofetil in the Treatment of Pediatric Anti-NMDAR Encephalitis: A Retrospective Analysis of 6 Cases

Abstract: Objective: To explore the effectiveness and safety of mycophenolate mofetil (MMF) as a second-line medication in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, the most common and severe autoimmune encephalitis.Methods: The clinical data of six children with anti-NMDAR encephalitis admitted to the First Hospital of Jilin University were retrospectively analyzed, and the effectiveness and safety of MMF were evaluated.Results: Six children with anti-NMDAR encephalitis were treated with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 23 publications
0
2
0
Order By: Relevance
“…Neurological disorders in patients with antibodies to cell surface membrane antigens, such as anti-NMDAR, involve potentially reversible neuronal receptor impairment. Successful treatment of these conditions, with marked patient improvement, has been repeatedly documented following the use of corticosteroids, plasma exchange, intravenous immunoglobulin G (IVIG), and corticosteroid-sparing immunosuppressive agents such as rituximab, cyclophosphamide, or mycophenolate mofetil (132)(133)(134). To date, no single agent or sequence of agents has been proven to be more effective, and optimal use of therapeutic agents and length of treatment await prospective controlled clinical trials.…”
Section: Issues and Implications For Patient Carementioning
confidence: 99%
“…Neurological disorders in patients with antibodies to cell surface membrane antigens, such as anti-NMDAR, involve potentially reversible neuronal receptor impairment. Successful treatment of these conditions, with marked patient improvement, has been repeatedly documented following the use of corticosteroids, plasma exchange, intravenous immunoglobulin G (IVIG), and corticosteroid-sparing immunosuppressive agents such as rituximab, cyclophosphamide, or mycophenolate mofetil (132)(133)(134). To date, no single agent or sequence of agents has been proven to be more effective, and optimal use of therapeutic agents and length of treatment await prospective controlled clinical trials.…”
Section: Issues and Implications For Patient Carementioning
confidence: 99%
“…Corticosteroids can be used as a bridging strategy, followed by a gradual taper over weeks to months, or even years, overlapping with long-term immunotherapy after completing acute therapy. The combination of corticosteroids and MMF is a common long-term immunotherapy, with MMF needing to overlap with corticosteroids for at least 3-6 months due to its delayed onset of action ( 11 , 13 ).…”
Section: Introductionmentioning
confidence: 99%